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Background: High levels of asthma-related fear and panic exacerbate asthma symptoms and
complicate the management of asthma. Asthma-specific fear may be reduced by a cognitive
behavioural intervention. We aimed to test if there is a reduction in asthma-specific fear after
cognitive behavioural intervention compared with routine treatment.
Methods: Adults with asthma registered with family doctors in Sheffield UK were screened for
anxiety and 94 highly anxious patients were randomly allocated to receive either a cognitive be-
havioural intervention to improve self-management of their anxiety (nZ 50) or routine clinical
care (nZ 44). Asthma-specific fear at the end of treatment and at six month follow up were the
primary endpoints. Service usage in the six months prior to and six months following the inter-
vention was monitored to allow estimation of costs. Data were analysed by intention to treat.
Findings: At the end of treatment, there was a significantly greater reduction in asthma-specific
fear for people in the CBT group compared with controls. At six months after treatment the
reduction in asthma-specific fear in the CBT group was increased and the difference between
treatment and control group was statistically significant. Service use costs were not reduced
in the CBT group.14 2220795.
ffield.ac.uk (G.D. Parry), c.l.cooper@sheffield.ac.uk (C.L. Cooper), peteandju@talktalk.net
(G. Yadegarfar), m.j.campbell@sheffield.ac.uk (M.J. Campbell), lisa_esmonde@hotmail.com
uk (A.H. Morice), bruce.hutchcroft@which.net (B.J. Hutchcroft).
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Trial of CBT in asthma and anxiety 803Interpretation: A brief cognitive behavioural intervention was found to have efficacy in reducing
asthma-specific panic fear immediately after treatment and at 6 months follow up. There was no
cost advantage to cognitive behavioural treatment.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Although anxiety is a normal reaction to extreme dysp-
noea,1 and may even be functional in moderation,2,3 high
levels of panic fear may lead both to exacerbation of the
condition and poor management. Panic may trigger an
asthma attack through hyperventilation and airways cool-
ing.4 Patients may find it difficult to distinguish between
the symptoms of anxiety and those of asthma, leading to
inappropriate self-medication.5 Most management errors in
acute severe asthma in adults are related to patient
behaviour, where panic and the overuse of b-agonists are
important contributory causes.6
As well as the importance to asthma patients of optimal
anxiety management, there are potential cost advantages
to the health system. There is a strong relationship
between a cluster of panic-fear symptoms during asthma
attacks, and a more stable trait of vulnerability to panic
fear, both of which correlate with service use, A&E atten-
dances, levels of medication, and length of hospitalisation,
independent of pulmonary function.7,8
Psychological interventions designed to help adults
manage their asthma include patient education, stress-
reduction through relaxation techniques, hypnotherapy,
EMG biofeedback, rational-emotive group therapy and
behavioural therapy,9e12 but these do not explicitly address
the needs of high panic-fear patients. Yorke, Fleming &
Shuldham13 reporting on a 2005 Cochrane Collaboration
meta-analytic systematic review14 identified 15 randomised
trials of psychological interventions for adults with asthma;
psychoeducation, relaxation, biofeedback and cognitive
behaviour therapy (CBT). They found some evidence of
improved quality of life following CBT after meta-analysis of
two trials by Put15 and Ross.16 These undertook randomised
controlled trials of CBTand psychoeducation compared with
waiting list controls. In terms of anxiety, Put (2003) demon-
strated no difference between groups whereas Ross (2005)
demonstrated a statistically significant effect on anxiety.
Neither of these studies included measures of depression.
These studies were small with methodological weaknesses.
Yorke, Fleming & Shuldham concluded that “The ability to
make firm conclusions as to the effectiveness of psycholog-
ical interventions was limited by poor study quality, insuffi-
cient reporting of data and varied outcomemeasures”. They
also pointed out that psychological interventions studies
oftendonot specifywhether the aimof treatment concerned
adjustment to asthma or to psychological co-morbidity, such
as asthma-specific fear.
The role of fear-provoking thoughts and catastrophic
interpretations of bodily sensations in the generation
of panic has been demonstrated in chronic obstructive
pulmonary disease (COPD)17 and this is likely to be similar
in asthma.
The role of dyspnoea in asthma panic fear and of anxiety
sensitivity has been investigated18,19 with the suggestionthat asthma might induce the expression of an underlying
vulnerability to panic. The sensation of suffocation is
central to both asthma and anxiety but in asthma the
‘suffocation alarm’ is a true one linked to peripheral
respiratory mechanisms, whereas in panic disorder, ’false’
suffocation alarms may be triggered by sensitivity to
anxiety.20 Current understanding and treatment of panic
fear and health anxiety focus on cognitive factors21 and
potentially cognitive therapy methods have much to offer
these patients, when combined with a behavioural
approach to asthma-specific coping skills. In 2008, Lehrer
et al.22 reported a pilot study of protocols combining CBT
for panic with both asthma psychoeducation and education
for differentiating panic and asthma symptoms. Ten
patients started treatment, with five completing.
Improvements were observed in panic, symptoms of asthma
and use of asthma medication. On this basis, the authors
recommended a controlled study. Although a CBT inter-
vention may improve clinical outcomes and reduce costs,
randomised controlled trials evaluating its efficacy or cost
effectiveness specifically in relation to asthma-specific fear
have not been reported.Methods
Patients
All general practices in Sheffield, UK were invited to
participate in the study and 14 practices expressed
interest. Family doctors were asked to refer those patients
with asthma whom they recognised as anxious, and in
addition, a screening questionnaire was sent to all regis-
tered adult patients with a diagnosis of asthma in those
practices via the practice. Participants were also recruited
from outpatient clinics and in-patient admissions by the
Consultant Respiratory Physicians collaborating with the
trial.
The eligibility criteria for the trial were (1) a clinical
diagnosis of asthma (defined as a clinical picture of airflow
obstruction with diurnal variation in symptomatology and
clinical evidence of airways hyper-irritability), (2) above
threshold on clinical criteria of anxiety, using published cut
off points for Hospital Anxiety Scale (HADS anxiety score)
and the Asthma Symptom Checklist panic fear sub-scale
(ASC-PF). We included those who had a score of 8 or more
on the HADS anxiety scale or 28 þ on ASC-PF.
Exclusion criteria were: (1) HAD anxiety score <4 (2) age
under 18 or over 65, (3) inability to read and complete
questionnaires in English, (4) severe psychiatric illness
(with history of hospital admission), (5) diagnosed heart
failure or angina, (6) significant co-morbid lung disease.
The sample was stratified by asthma severity and socio-
economic group. Forced expiratory volume (FEV1) was
measured. Objective evidence of the severe asthma was
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compared with the predicted normal function for someone
of that age and sex. Reversibility of airway obstruction was
also recorded. Participants were assigned, on the basis of
the occupation of their household’s main wage earner, to
Socio-Economic Groups I, II, IIINM (non-manual), IIIM
(manual), IV and V. The SEGs were then collapsed into two
categories: Upper (SEG I, II and IIINM) and Lower (SEG IIIM,
IV and V).
Recruitment: Patients were seen in the hospital outpa-
tient clinic and those meeting trial eligibility criteria were
consented into the trial by one of two Consultant Physicians
in the following way: (1) The research physician discussed
the trial with potential participants and, for those inter-
ested in being involved, confirmed they met all eligibility
criteria except for those related to anxiety and depression.
(2) Those meeting these eligibility criteria were then asked
to complete the assessment questionnaire comprising the
ASC, EQ5D, HADs, AMHLC and the Asthma Bother Profile,
demographic and socio-economic status questions. Those
meeting the anxiety and depression eligibility criteria were
consented into the trial. These data comprised the baseline
data.
An independent statistician who was a member of the
data monitoring group generated a blocked and stratified
by asthma severity and socio-economic status random-
isation schedule by computer (Random Log). In order to
undertake randomisation, calculation of socio-economic
status and confirmation of asthma severity was required.
This information was not always available at the time of
consent so treatment allocation was done by the research
associate when this information was available. The
research associate assigned the participants to treatment
groups in strict sequential order according to the schedule
and informed them of the allocation by telephone.
The study protocol was reviewed by both North and
South Sheffield Local Research Ethics Committees.Intervention
The intervention combined education about asthma and
anxiety with cognitive behavioural therapy, and was
designed to improve self-management of asthma-specific
fear. All patients received a booklet giving information
about asthma, asthma medication, and the effects of
anxiety, anxious thoughts and hyperventilation. All patients
discussed this with their therapist. For every patient, the
therapist made a cognitive behavioural formulation of the
patient’s asthma-specific fear problems, based on an
analysis of the functional relationship for each individual
between situational triggers, asthma-related beliefs and
assumptions, cognitions, attentional focus, and physiolog-
ical factors.
On the basis of this formulation, the therapy could
include the following specific elements: (1) explanation of
the nature of breathing difficulties in asthma and in
anxiety, and the differences between them to improve the
patient’s discrimination between asthma and anxiety
symptoms, (2) promoting awareness of anxiety-provoking
cognitions through self-monitoring, particularly cata-
strophic misinterpretations of somatic sensations, andlearning how to generate alternative evidence-based
cognitions, (3) reducing dysfunctional somatic preoccupa-
tion by retraining focus of attention, (4) reducing
dysfunctional safety-seeking by controlled exposure to
anxiety and increasing anxiety tolerance, (5) learning
methods to recognise and control hyperventilation,
including good breathing technique, postural adjustments,
and relaxation, (6) identifying triggers to panic fear, (7)
developing the patient’s skill in problem-solving and
systematically generating and testing hypotheses on the
most appropriate way to manage the asthma episode, (8)
exploration of problematic asthma-related beliefs and
assumptions revealed through the above methods.
The intervention consisted of an introductory session of
1.5 h followed by 4e6 sessions of 1 h, either weekly or
fortnightly, with two follow up sessions of 1 h each if
considered necessary by patient and therapist.
Four therapists participated in the study. Three were
clinical psychologists and one was a cognitive behavioural
therapist from a mental health nursing background. All
were trained and experienced in cognitive behavioural
therapy, but none had specialised in asthma before the
project began. Fortnightly peer supervision was provided in
the early stages from an external supervisor and later, in
a peer supervision group throughout the project. Within the
overall guidelines for a) the focus of the intervention, b)
the formulatory framework, and c) the elements of the
intervention, the therapists were free to exercise their own
judgement on how to deliver the treatment, consistent
with normal clinical practice. A structured case record of
the content of each session was kept and sessions were
audio-taped.
Objective
To compare the clinical, psychological and quality of life
outcomes, and use of services, for a randomly selected
group of patients with asthma and psychological compli-
cations receiving a brief cognitive behavioural intervention,
compared to a control group receiving standard medical
treatment.
Measures
The primary clinical outcome measure was the panic-fear
sub-scale of the Asthma Symptom Checklist, a self-report
measure of asthma-specific fear, at 6 months after the end
of treatment.23 We used the nine item version of ASC panic
fear with response options of 1e5 with a score of 28 or
above representing the cut off for clinically significant
panic fear. The cut off was derived from conventional
practice of considering an average item score of 3 or more
to be in the clinical range24 where lower scores represent
lower anxiety.
Secondary outcomes were assessed as follows:
Euroqol (EQ-5D), a generic measure of health status and
functioning, comprises three levels of response to five
questions (on mobility, self-care, usual activities, pain or
discomfort, anxiety or depression) and a general health
self-rating on a visual analogue scale.25 All possible
combinations of responses yield 243 health states. Health
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tions of these states, where 0 represents death and 1 best
possible health status.
The Hospital Anxiety and Depression Scale (HADS)26
consists of 14 items with two sub-scales measuring symp-
toms of depression and symptoms of anxiety. Scores of
8e10 on either sub-scale indicate possible clinical levels of
anxiety or depression.
Asthma-specific health-related quality of life measure
(Asthma Bother Profile)27 comprises 24 dimensions with six
response categories raging from ‘no bother at all’ to ‘makes
my life a misery’. Lower scores indicate higher quality of
life. The dimensions were grouped into 4 sub-scales
(activities, daily living, worry and primary care).
Asthma-specific health attitudes measure (Asthma
Multidimensional Health Locus of Control; AMHLC)28 was
derived from a well known general health locus of control
measure and has 24 items measuring three dimensions of
locus of control beliefs; internal locus of control, powerful
others externality and chance expectancy. Scores on each
dimension can range from 1 to 6, with low scores repre-
senting low rating on that dimension.
Measures were obtained by self-completion question-
naire at time of consent into trial (baseline), at end of
treatment (endpoint 1) and at 6 months after end of
treatment (endpoint 2). For control participants, time-
points were at time of consent into trial (baseline), and
then 3 months (endpoint 1) and 9 months (endpoint 2) after
baseline measures.
Use of resources by the participants was determined
using data on general practice surgery consultations, GP
call outs, prescribed medication, and hospital admissions.
These were obtained from general practice case notes, and
hospital computer records, with the consent of the patient.
Use of resources in the six months prior to participant entry
into the trial was compared with use in the three months
from start of treatment and in the three months period
after six months follow up. In addition the cost of assess-
ment and therapeutic intervention was estimated based on
the hourly rate for the therapists.Statistical analysis
To detect a clinically meaningful change of 0.5 standard
deviations on the continuously distributed measure of
asthma symptoms (ASC) with 80% probability (b Z 0.2) and
a 5% (two-sided) significance threshold (a Z 0.05), 64
patients were required in each group. After 94 participants
had been consented into the trial, recruitment was termi-
nated on the advice of the data monitoring group. This was
because the planned end-date had passed, funding had
been exhausted, participant recruitment was slow and
drop-out rate was high, particularly in the treatment group
at the point after the consent procedure but before
attending the first therapy session.
Two separate longitudinal comparisons were made for
each outcome indicator: treatment versus control at
endpoint 1 and treatment group versus control at
endpoint 2.
The main analyses were by intention to treat to reduce
bias due to differential attrition from the intervention andcontrol groups. For participants withdrawn on the basis of
clinical assessment (Fig. 1) data at endpoint 1 and 2 were
imputed as zero change as it was assumed that these
participants would not have benefited from CBT. For all
other missing data imputation was last observation carried
forward.
For all outcomes, mean scores at baseline and follow up
(baseline to follow up) were compared using t-tests. The
95% confidence interval of the difference in mean scores
between treatment and control groups was also calculated.
The change score, and difference (95% CI) in mean change
scores was calculated by subtracting the follow up score
from the baseline score. Finally, analysis of covariance
(ANCOVA) was carried out to correct for imbalances
between the treatment and control groups at baseline. The
covariates included in this analysis were score at baseline,
age, sex and smoking.
A supplementary complete case analysis was also carried
out for all outcomes using only cases with complete data
with no imputation.Results
Ninety-four participants were randomised to treatment
(n Z 50) and control (n Z 44) groups. A total of 88
participants completed baseline questionnaires (47 treat-
ment and 41 controls). Of the 47 allocated to the CBT
group, eight were withdrawn on the basis of post-
randomisation pre-therapy clinical assessment because
the therapist considered that the intended intervention
would be inappropriate or unhelpful for them and that they
should be referred for an alternative psychiatric or
psychotherapeutic treatment. This was either on the basis
of psychiatric co-morbidity revealed at clinical assessment
(e.g. anxiety was secondary to major depression and not
asthma-related, co-morbid personality disorder or alcohol
dependence) or the patient was unwilling to undertake
a CBT self-management programme. A further seven did not
attend the first appointment and were lost to follow up. Of
the 32 who began treatment, 18 completed the course of
sessions. End of treatment measures were obtained for 20
participants, 17 who completed treatment and three who
did not. Of the 41 allocated to the control condition and
completing baseline questionnaires one participant was
withdrawn on the basis of clinical assessment, 29
completed first endpoint measures. Participants in the
control arm were not routinely clinically assessed but
a special case was made for the one participant for whom it
was uncertain whether or not they met the eligibility
criteria related to concomitant psychiatric history. This
participant was subsequently withdrawn after random-
isation. At the second endpoint, after concerted efforts to
follow up dropouts, 59 participants completed measures
(28 in the CBT group, 15 of whom had completed treat-
ment, and 31 controls) (see Fig. 1). The mean time to
collection of the second endpoint data was 53 weeks for the
treatment group (range 35e74 weeks) and 51 weeks for the
control group (range 37e74 weeks).
The participants from the CBT and the control groups
for whom second endpoint measures were obtained did
not differ significantly on age and sex distribution,
Randomised = 94
Allocated to CBT = 50 Allocated to Control = 44
3 did not complete 
T1 measures 
n = 47
8 withdrawn – 
clinical assessment 
7 never 
attended
32 started CBT 
T2 measures 
n = 20 
18 completed 
treatment 
2 did not 
complete T1
1 withdrawn – 
not eligible
T1 measures 
n = 41 
1 withdrawn – 
clinical assessment 
T2 measures 
n = 29 
T5 measures  
n = 28
T5 measures 
n = 31
Figure 1 Flow chart of trial participation.
806 G.D. Parry et al.socio-economic status or clinical severity of asthma, and
both were similar to those who dropped out of treatment or
were lost to follow up on these characteristics. The sample
was predominantly female (ratio of 2:1) and had an average
age of 44.1 years (range 21e65; SD Z 11.7). (see Table 1).
All randomised patients were followed up and included
in the analysis where data were available, irrespective of
whether they completed treatment. More participants
completed outcome measures at the second endpoint thanTable 1 Baseline data: demographic & clinical characteristics.
CBT ITT n Z 28 Cont
Age: mean (range) 47.0 (28e65) 43.8
Sex (% women) 60.7 64.5
Socio economic status (% lowerb) 64.3 67.7
Severe asthmaa (%) 39.3 38.7
a Scoring greater than 25 percent reduction of FEV1.
b (IIIM, IV and V).at the first endpoint. The numbers analysed for each group
were as follows: first endpoint: 20 CBT, 29 control; second
endpoint: 28 CBT, 31 control.
For the ITT analysis there was a reduction in ASC panic
fear scores in the CBT group at the end of treatment (1.20
S.D. Z 3.71) which was statistically significant. The
ANCOVA found a significant net reduction in score of 2.59
(95% CI Z 4.39 to e0.79: p Z 0.005). Note that the
analysis using the unadjusted scores did not meet therol ITT n Z 31 CBT withdrawn
or lost to follow
up n Z 22
Control withdrawn
or lost to follow up
n Z 13
(25e61) 40.3 (21e63) 41.2 (32e64)
76.2 53.8
59.1 46.2
27.3 30.8
Figure 2 Change in ASC panic fear. Complete case analysis.
Trial of CBT in asthma and anxiety 8070.5 S.D. difference that we identified as clinically mean-
ingful. This level is only reached using the adjusted ANCOVA
analysis.
At 6 months after treatment the absolute reduction in
ASC panic fear score in the treatment group was increased
(3.34, SD 5.39), and there was still a significant difference
between treatment and control groups although the levels
of panic fear in the control group had also reduced (see
Table 2).
However, for the completed case analysis, there was
a significant net reduction in ASC panic fear in the CBT
group compared with the control group at the end of
treatment and at the end of follow up but the reduction
was only statistically significant at the end of treatment
(Fig. 2 and Table 3).Secondary analyses
The above analyses were repeated for the secondary
measures. For the ITT analysis with imputation the CBT
group showed reductions in both HAD depression (0.50
S.D. Z 1.87) and the daily living dimension of the asthma-
specific quality of life measure (0.78 S.D. Z 2.36) indi-
cating an increase in quality of life at endpoint one. The
reductions in both HAD depression and asthma-specific
quality of life were statistically significant compared with
changes in controls (ANCOVA - 1.0; 95% CIZ 2.0 to 0.1:
p Z 0.04 and 1.18 95% CI Z 2.26 to 0.10).The
proportion of participants with a HAD score of eight or more
(the threshold for possible clinical depression) in the
treatment group was 35% at baseline compared with 30% at
endpoint one. The proportions in the control group were
39% and 52% respectively. However, the effect was no
longer evident for HAD depression or asthma-specific
quality of life at six months after treatment (HAD differ-
ence 0.5; 95% CI Z 1.9 to 0.8: and ASQoL difference
0.8 95% CI Z 2.1 to 0.6). There were no significant
differences in the other sub-scales of the ASQoL measure at
either endpoint for either analysis. There was no significantTable 2 Change in ASC panic fear. Intention to treat analysis.
ASC9 score (mean & SD)
Control n Z 41
Baselinea (T1) 27.13 (8.43) n Z 39
Follow-up endpoint 1 (T2): end
of treatment
28.05 (8.25) n Z 40
Change (T1 e T2) 1.10 (3.91) n Z 39
ANCOVAb (T1eT2) e
Follow-up endpoint 2 (T3): 6 months
after end of treatment
25.22 (9.16) n Z 41
Change (T1 e T3) 1.08 (4.83) n Z 39
ANCOVAa (T1eT3) e
a At baseline, only 79 observations were available for ASC9 scores.
b ANCOVA included Baseline ASC9, age, group (0 Z Control, 1 Z
(0 Z Never or Ex-smoker & 1 Z Current smoker). 3 missing smoking
total number became 76 (79-3 missing smoking).difference in HAD anxiety scores between groups at either
time-points for either analysis.
The CBT and control groups did not differ significantly
on the EQ5D at the end of treatment, but at 6 months after
treatment there was a significant reduction in EQ5D scores
for the treatment group compared with controls, indicating
a reduction in generic health status for the treatment
group (ANCOVA - 0.11: 95% CIZ 0.20 to 0.03: pZ 0.012
and 0.12 95% CI Z 0.25 to 0.02 for ITT and complete
case analysis respectively). No differences between the
groups were found on the EQ5D visual analogue scale. This
result was anomalous, given the improvement in ASC panic
fear for the treatment group. To explore this further, we
examined the five dimensions of the EQ5D separately and
inspected the distributions for outliers. There seemed to
be modest but consistent differences between the treat-
ment and control groups for all dimensions. There were no
pre-treatment differences between the treatment and
control groups on mean EQ-5D scores. The unpredicted
result is therefore not attributable to a single dimension or
to more severely ill individuals in the treatment group.
There was a small and not statistically significant
increase in internal locus of control in treatment partici-
pants compared with controls at end of treatment whichDifference in means
(95% CI)
P-value
Treatment n Z 47
24.83 (8.92) n Z 40 2.30 (6.19 to 1.59) e
24.19 (9.75) n Z 42 3.86 (7.87 to 0.15) 0.06
1.20 (3.71) n Z 41 2.30 (3.99 to 0.60) 0.01
e 2.59 (4.39 to 0.79)
n Z 76
0.01
22.47 (9.08) n Z 43 2.75 (6.71 to 1.21) 0.17
3.34 (5.39) n Z 41 2.26 (4.55 to 0.02) 0.05
e 2.87 (5.12 to 0.62)
n Z 76
0.01
Treatment), gender (1 Z Male & 2 Z Female), and smoking
status, therefore, as ASC9 score was available for 79 individuals,
Table 3 Change in ASC panic fear. Complete case analysis.
ASC9 score (mean & SD) Difference in means (95% CI) P-value
Control n Z 41 Treatment n Z 47
Baseline (T1)a 26.48 (9.00) n Z 25 26.82 (8.00) n Z 17 0.34 (5.13e5.82) e
Follow-up endpoint 1 (T2) 28.2 (9.10) n Z 25 23.94 (9.88) n Z 17 4.26 (10.25 to 1.73) 0.16
Change (T1 e T2) 1.72 (4.80) n Z 25 2.88 (5.41) n Z 17 4.60 (7.81 to 1.39) 0.01
ANCOVAb (T1eT2) e e 5.15 (8.34 to 1.96) n Z 42 0.002
Follow-up endpoint 2 (T3) 24.83 (7.71) n Z 23 20.78 (8.07) n Z 23 4.04 (8.73 to 0.65) 0.09
Change (T1 e T3) 2.43 (5.54) n Z 23 5.04 (6.20) n Z 23 2.61 (6.10 to 0.89) 0.14
ANCOVAa (T1eT3) e e 2.55 (5.77 to 0.66) n Z 46 0.12
a T1 measurements accompanied by either T2 or T3 measures were included.
b ANCOVA included Baseline ASC9, age, group (0 Z Control, 1 Z Treatment), gender (1 Z Male & 2 Z Female), and smoking
(0 Z Never or Ex-smoker & 1 Z Current smoker). 3 missing values for smoking status.
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the end of six months follow up (ITT ANCOVA 2.71: 95% CI
0.56 to 4.85 p Z 0.014). The results were similar in direc-
tion for the complete case analysis but not statistically
significant (ANCOVA 4.27 95% CI 3.30 to 11.84 pZ 0.262).
Service use in the treatment and control groups was
examined as a basis for direct cost estimation (see Table 4).
There were no statistical differences between the groups
on any of the service use indicators, although there was
a slight increase in GP consultations in the CBT group during
the treatment period.
The intervention itself cost an average of between £378
and £798 per participant depending on the number of
sessions attended and given the absence of any cost offset,
the treatment has no cost advantage.
Adverse events
One patient in the CBT arm, with severe asthma, died of an
asthma attack between the first and second endpoints.
Discussion
The short and longer term efficacy of a brief cognitive
behavioural intervention designed to reduce asthma-Table 4 Service use in CBT and control groups.
CB
General practice consultations
(mean, SD)
Pre 1
During 3.
After 1
Total PC contact (includes
asthma nurses and out-of-
hours)
Pre 1.
During 3.
After 1.
Prescribed medication; no of
scripts (mean, SD)
Pre 1.
During 1.
After 1.
Number of patients with
Hospital admissions Total
Pre 3
Pre Z six months prior to treatment.
During Z during treatment.
After Z six months after treatment phase.specific fear has been demonstrated. There was no
impact on general levels of anxiety. The end-of treatment
reduction in panic fear in the treatment group was main-
tained at 6 month follow up and despite a (smaller)
reduction in the control group there was statistically
significant difference in reduction of panic fear in the
treatment group compared with control. Therefore,
although recruitment to this study was slower, and the
sample size smaller than intended there is sufficient
evidence to indicate that improvement relative to usual
treatment is maintained after the end of treatment.
There were also significant improvements in asthma-
specific quality of life and depression following CBT
compared with controls, but these were not maintained at
six month follow up. The proportion of participants in the
treatment group with possible clinical depression reduced
from 35% at baseline to 30% at endeof-treatment. The
asthma-specific quality of life scale is not anchored to
clinical benefit.
These findings should be interpreted with some caution
due to a methodological limitation of the trial. The clinical
assessment was conducted post-randomisation prior to
treatment commencing, and at this point eight patients in
the CBT group and one in the control group were referred
out of the trial to alternative treatments. Despite the fact
that the intention-to-treat analysis imputed zero changeT group Control group t-value (p)
.6 (1.6) 2.2 (2.4) 0.884 (0.38)
47 (4.8) 2.59 (2.7) 0.66 (0.52)
.8 (1.5) 2.08 (3.1) 0.433 (0.67)
63 (1.6) 2.30 (2.5) 1.13 (0.27)
47 (4.8) 2.73 (2.7) 0.557 (0.59)
87 (1.73) 2.27 (3.1) 0.596 (0.55)
53 (0.92) 1.43 (1.4) 0.259 (0.80)
33 (1.4) 1.32 (1.1) 0.02 (0.98)
27 (1.3) 1.00 (1.3) 0.686 (0.50)
4
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sion in the trial would have affected the result
unfavourably.
Findings on service use showed no difference between
the CBT and control group. As the CBT group had incurred
greater costs and there was no cost offset for the treated
group the intervention was not found to have a cost
advantage.
What is the external validity of these findings, and their
implications for practice? Although there was a statistically
significant difference between the CBT and the control
group at the end of therapy and at 6 months follow up,
absolute magnitude of the difference in the ASC panic fear
scores in the treated group was modest (about 3 scale
points) and at the end of follow up, 22% of the treated
group were still in the clinical range for asthma-specific
fear. The clinical significance of this finding is therefore
modest.
We found that in practical terms, panic fear or other
anxiety complications of asthma were largely unrecognised
in community or hospital clinics. Practices participating in
the study spontaneously identified only one, two or three
patients that they felt met this criterion, but when the
screening questionnaire was sent to all registered patients
with asthma, between 10 and 24 patients per practice met
criteria for asthma-specific fear. A number of these
patients, even if initially consenting to the trial, did not in
the event wish to participate in a psychological treatment
(shown by the high rate of non-attendance at the first
session in the CBT arm). This suggests that screening
asthma patients for panic fear may identify those who do
not feel themselves to be in need of such a service,
possibly linked to an avoidant coping style. Similar
recruitment and retention difficulties have been reported
in an RCT of CBT for chronic obstructive pulmonary disease
(COPD). Kunik29 reports that of 1981 people identified as
eligible through telephone screening only 258 were subse-
quently consented, 16 of these dropped out before ran-
domisation and of the 118 randomised to CBT only 89
attended at least one session. At 8 months (equivalent to 6
months post intervention) data were available for only 50
participants in the CBT arm, that is 42% of those rando-
mised compared with 56% retention in this study. The
important issue is that the eligibility criteria for future
studies should include a more detailed screening of will-
ingness of participants to undertake CBT and assessment of
the suitability of CBT for the participants. This would
ensure that trial participants were more similar to those
likely to receive CBT in practice, increase external validity
and reduce attrition.
In relation to beliefs about asthma, six months after
treatment ended, participants in the CBT group felt they
had greater control over their asthma symptoms and were
less likely to attribute these to external factors. This is
consistent with the aims of the cognitive behavioural
intervention.
We were not able to explain the small but significant
reduction in EQ5D scores for the treatment group at six
month follow up, compared with controls, showing that this
group had greater reduction in overall health status. It may
have been a psychological effect of loss of support, due to
the end of participation in the trial. This effect would notbe as marked for control participants, as they had not
developed a relationship with the therapist. However, this
does not explain why other measures were unaffected.
This study supports the short term and longer term
efficacy of a CBT intervention in reducing panic fear in
asthma, though the clinical significance of the effect was
modest.
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